1. Show article details.

    BRIEF-Aerami Therapeutics Appoints Barry Deutsch As Chief Financial Officer

    Reuters – 8:41 AM ET 11/18/2021

    Xeris Biopharma Holdings Inc (XERS): * AERAMI THERAPEUTICS APPOINTS BARRY DEUTSCH AS CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

  2. Show article details.

    Aerami Therapeutics Appoints Barry Deutsch as Chief Financial Officer

    GlobeNewswire – 8:30 AM ET 11/18/2021

    Aerami Therapeutics, Inc., a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Barry Deutsch as chief financial officer effective November 15, 2021.

  3. Show article details.

    BRIEF-Xeris Biopharma Reports Third Quarter 2021 Financial Results And Other Highlights

    Reuters – 7:08 AM ET 11/10/2021

    Xeris Biopharma Holdings Inc (XERS): * XERIS BIOPHARMA REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS AND OTHER HIGHLIGHTS. * SEES FY SALES $38 MILLION TO $40 MILLION. * BELIEVES CASH RESOURCES SUFFICIENT TO SUSTAIN OPERATIONS THROUGH AT LEAST END OF 2022.

  4. Show article details.

    Xeris Biopharma Reports Third Quarter 2021 Financial Results and Other Highlights

    Business Wire – 7:00 AM ET 11/10/2021

    Acquisition of Strongbridge Biopharma closed October 5, 2021; integration complete Q3 pro forma net sales of $22.5M: Gvoke® and Keveyis® $11.0M and $11.5M, respectively Gvoke and Keveyis net sales grew 19% compared to Q2 2021 and combined are on track to achieve $76M to $80M full year 2021 net sales On track to realize $50M in synergies; anticipates year-end cash, cash equivalents, and invest...

  5. Show article details.

    Xeris Biopharma to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 10, 2021

    Business Wire – 7:30 AM ET 11/02/2021

    Xeris Biopharma Holdings, Inc. (XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that the Company will release its third quarter 2021 financial results before the open of the U.S. financial markets on Wednesday, November 10, 2021.

  6. Show article details.

    BRIEF-Xeris Pharmaceuticals Enters Collaboration Agreement With Merck

    Reuters – 7:58 AM ET 10/25/2021

    Xeris Biopharma Holdings Inc (XERS): * XERIS PHARMACEUTICALS ENTERS COLLABORATION AGREEMENT WITH MERCK. * XERIS BIOPHARMA (XERS) - COLLABORATION AGREEMENT WITH MERCK, WITH OPTION TO LICENSE CO'S SUSPENSION-BASED FORMULATION TECHNOLOGY, XERIJECT. * XERIS BIOPHARMA (XERS) - TERMS OF AGREEMENT WERE NOT DISCLOSED Source text for Eikon: Further company coverage:

  7. Show article details.

    Xeris Pharmaceuticals Enters Collaboration Agreement With Merck

    Business Wire – 7:30 AM ET 10/25/2021

    Collaboration and option to license the XeriJect™ technology Xeris Biopharma Holdings, Inc. (XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced a collaboration agreement with Merck, with an option to license Xeris’ suspension-based formulation technology, XeriJect™, for use with u...

  8. Show article details.

    Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma

    Business Wire – 4:05 PM ET 10/05/2021

    Xeris Pharmaceuticals, Inc. (XERS) and Strongbridge Biopharma plc (SBBP) are now subsidiaries of Xeris Biopharma Holdings, Inc. Xeris Pharmaceuticals, Inc. (XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge...

  9. Show article details.

    Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

    GlobeNewswire – 4:01 PM ET 10/05/2021

    Strongbridge Biopharma plc (SBBP) today announced that the High Court of Ireland has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (XERS) by means of a scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014.

  10. Show article details.

    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Business Wire – 4:05 PM ET 10/01/2021

    Xeris Pharmaceuticals, Inc. (XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on October 1, 2021, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 28,750 shares of its common stock to 20 new employee under Xeris’ I...

  11. Show article details.

    Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

    Business Wire – 8:00 AM ET 09/17/2021

    Xeris Pharmaceuticals, Inc. (XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals (XERS), will present an overview of the Company at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September ...

  12. Show article details.

    BRIEF-Xeris Pharmaceuticals Stockholders Approve Acquisition Of Strongbridge Biopharma

    Reuters – 4:09 PM ET 09/14/2021

    Strongbridge Biopharma plc (SBBP): * XERIS PHARMACEUTICALS STOCKHOLDERS APPROVE ACQUISITION OF STRONGBRIDGE BIOPHARMA Source text for Eikon: Further company coverage:

  13. Show article details.

    Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharma

    Business Wire – 4:05 PM ET 09/14/2021

    Xeris Pharmaceuticals, Inc. (XERS) today announced that its stockholders have voted to approve the previously announced proposed acquisition of Strongbridge Biopharma plc (SBBP) by Xeris.

  14. Show article details.

    Strongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris Pharmaceuticals, Inc.

    GlobeNewswire – 4:01 PM ET 09/08/2021

    Strongbridge Biopharma plc (SBBP) today announced that its shareholders have voted to approve the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (XERS). As described below, at least 99 percent of the votes cast at both a special court-ordered meeting of shareholders and at an extraordinary general meeting of shareholders were in favor of the transaction, representing...

  15. Show article details.

    Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

    GlobeNewswire – 7:30 AM ET 08/31/2021

    Glass Lewis Joins ISS in Recommending Strongbridge Shareholders Vote “FOR” Transaction with Xeris Strongbridge Urges Shareholders to Vote “FOR” All Transaction-Related Proposals Strongbridge Biopharma plc (SBBP) today announced that Glass Lewis & Co. has recommended that Strongbridge shareholders vote “FOR” all proposals related to the Company’s transaction with Xeris Pharmaceuticals.

  16. Show article details.

    Leading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xeris

    GlobeNewswire – 7:30 AM ET 08/30/2021

    Strongbridge Biopharma plc (SBBP) today announced that the leading independent proxy advisory firm Institutional Shareholder Services has recommended that Strongbridge shareholders vote “FOR” the Company’s transaction with Xeris Pharmaceuticals (XERS). In its August 27, 2021 report, ISS recognized the substantial upside potential of the combined company for Strongbridge shareholders.

Page:

Today's and Upcoming Events

No events in the next 90 days

Past Events (last 90 days)

  • Nov
    10

    XERS announced Q3 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.